Topical metronidazole combination therapy in the clinical management of rosacea.
Metronidazole was the first topical agent approved by the U.S. Food and Drug Administration for the treatment of rosacea. Several controlled studies have confirmed the efficacy and safety of topical metronidazole 0.75% gel, lotion and cream and 1% cream for rosacea. At present, little data exists regarding the use of combination topical therapy in rosacea management, although anecdotal evidence and preliminary studies suggest at least some additive benefit when topical metronidazole is used in combination with sulfacetamide 10% /sulfur 5%. In this paper, the results of observational experience evaluating topical metronidazole 0.75% gel used in combination with other topical rosacea therapies and/or subantimicrobial dose doxycycline are reported.
Del Rosso
James Q
JQ
Department of Dermatology, University of Nevada School of Medicine, Las Vegas, NV, USA.
Bikowski
Joseph
J
D000287:Administration, Topical; D000328:Adult; D000368:Aged; D019468:Disease Management; D004318:Doxycycline / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008795:Metronidazole / Q000008:administration & dosage*; D008875:Middle Aged; D012393:Rosacea / Q000188:drug therapy* / Q000473:pathology; D013409:Sulfacetamide / Q000008:administration & dosage
D008795:Metronidazole; D013409:Sulfacetamide; D004318:Doxycycline